Ofichem has consolidated its multiple business units into a single CDMO and pharmaceutical supply organisation, bringing together its API production, formulation, and distribution capabilities under one unified brand.

From April 1, the company’s former entities — including Ofichem BV, Ofipharma, Ofimedicine, Labatorium Ofichem, Ofichem Uppsala, and Avivia — now operate under a single trading name as part of a move to simplify engagement for pharmaceutical and biotech customers seeking more integrated, end-to-end development and manufacturing partners.

As part of the transition, Ofichem said it aims to provide a clearer view of its capabilities while maintaining existing standards of quality, compliance, and service. The company operates across API production, formulation, and supply chain services, and positions the integration as a response to increasing customer demand for fewer, more comprehensive supplier relationships.

“Over time, we’ve built a business with real depth across API, drug substance, drug product and supply,” said Weite Oldenziel, chief executive of Ofichem. “What has been less visible is how those capabilities come together. Combining all brands under the Ofichem umbrella makes that clear as we continue to support our customers in a more connected and consistent way.”

Oldenziel added that the change is intended to improve clarity rather than alter the company’s operational model.

“This is not a change to what we do, but to how clearly we present it,” he said. “Our customers can expect the same reliability and flexibility, now with greater visibility of our comprehensive support as we strive to give every medicine the best chance of fulfilling its potential.”

The company also highlighted its position as a European CDMO partner, emphasising regulatory expertise, supply chain reliability, and collaboration in a market increasingly focused on security, transparency, and control.